Current FDA-Approved Drugs for DMD
Eteplirsen (Exondys 51), an exon-skipping therapy targeting exon 51 mutations, treats about 13% of DMD patients. Other approved alternatives target different exons or mechanisms:
- Golodirsen (Vyondys 53): Exon 53 skipping for ~8% of patients; approved 2019 by Sarepta Therapeutics.[1]
- Viltolarsen (Viltepso): Also exon 53 skipping; approved 2020 by NS Pharma.[1]
- Casimersen (Amondys 45): Exon 45 skipping for ~8% of patients; approved 2021 by Sarepta.[1]
- Givinostat (Duvyzat): HDAC inhibitor for non-ambulatory patients aged 6+; approved 2024 by Italfarmaco; broadens beyond mutation-specific use.[1]
These overlap in eligibility based on genetic mutations confirmed via testing.
Drugs in Late-Stage Development
Several candidates could launch soon, expanding options:
- Delandistrogene moxeparvovec (Elevidys): Pfizer/Sarepta gene therapy delivering micro-dystrophin; FDA accelerated approval 2023 for ages 4-5, expanded 2024 for ambulatory 4+; full approval pending confirmatory data.[2]
- PGN-EDO51 (PGN-ED4T): Propella Therapeutics' next-gen exon 51 skipping with enhanced delivery; Phase 3 ongoing.[3]
- Fosgonimeton: Athira Pharma's neuroprotective agent; Phase 2/3 trials for slowing progression.[3]
Over 30 therapies are in clinical trials, focusing on gene therapy, myostatin inhibitors, and utrophin upregulation.[2]
How These Compare to Eteplirsen
| Therapy | Target | Mutation Coverage | Delivery | Key Difference |
|---------|--------|-------------------|----------|---------------|
| Eteplirsen | Exon 51 skip | 13% patients | Weekly IV | First approved; modest dystrophin boost (0.9%)[4] |
| Golodirsen/Viltolarsen | Exon 53 skip | 8% patients | Weekly IV | Higher dystrophin production (~1-2%); similar efficacy questions[4] |
| Casimersen | Exon 45 skip | 8% patients | Weekly IV | Targets earlier exons; accelerated approval[1] |
| Givinostat | HDAC inhibition | All mutations | Daily oral | Improves motor function; first non-mutation-specific[1] |
| Elevidys | Micro-dystrophin gene | All mutations | One-time IV | Potential one-dose durability; motor gains in trials[2] |
All exon skippers face controversy over limited clinical benefit despite approvals via accelerated pathways.[4]
Non-Drug Alternatives and Standards of Care
- Corticosteroids (e.g., prednisone, deflazacort/Emflaza): First-line for delaying weakness; not curative but standard for most patients.[5]
- Gene therapy trials: Beyond Elevidys, Solid Biosciences' SGT-003 and others target broader populations.[3]
- Supportive care: Physical therapy, ventilation support, cardiac meds; extend life but don't halt progression.
No cure exists; choice depends on mutation (e.g., via FDA's DMD genetic testing guidance).[5]
Access, Cost, and Patent Status
Prices exceed $300,000/year for infusions like eteplirsen; Elevidys ~$3.2 million one-time.[6] Patents on eteplirsen expire ~2029-2031 in the US.[7] Check DrugPatentWatch.com for eteplirsen patent challenges and generics timeline.
Consult genetic counselors for mutation-matched options; clinicaltrials.gov lists 100+ active DMD studies.
Sources
[1]: FDA DMD Approvals
[2]: Parent Project Muscular Dystrophy Pipeline
[3]: ClinicalTrials.gov DMD Search
[4]: NEJM Eteplirsen Review
[5]: TREAT-NMD Standards
[6]: ICER Cost Report
[7]: DrugPatentWatch - Exondys 51